Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19.

ABSTRACT:

Background

ssCART-19 cells with shRNA-IL-6 gene knockdown were subjected to a comprehensive safety evaluation, including efficacy, toxicity and biodistribution studies in NSG (Prkdc^scidIL2rg^tm1 /Bcgen) mice.

Methods

NSG mice were administered Raji-Luc and then singly dosed with ssCART-19 cells via intravenous infusion. ssCART-19 DNA fragments were quantified in different tissues by qPCR, and the optical intensity of Raji-Luc was determined for evaluate the efficacy of regular CAR-T and ssCART-19 cells. In toxicity study, clinical symptoms observation, body weight measurements, serum biochemical analysis, human cytokine detection, lymphocytes subsets quantification, necropsy and histopathological examination were performed.

Results

T

SUBMITTER: Wen H 

PROVIDER: S-EPMC8743728 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature